Skip to main content

Winston Roy's Form 4 filing

Pacira BioSciences, Inc. (PCRX) · filed Jun 8, 2022

Accession no.
0001209191-22-035234
Filed
Jun 8, 2022
Trade date
Jun 6-8, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 11 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.08M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Winston RoyCIK 0001751757Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 6, 2022Common StockSSaleDisposed−2,099$61.37−$128,815.6344,357Direct
Jun 6, 2022Common StockMOption exerciseAcquired+6,250$34.38+$214,87550,607Direct
Jun 6, 2022Common StockSSaleDisposed−2,535$60.55F3−$153,494.2548,072Direct
Jun 6, 2022Common StockSSaleDisposed−2,300$61.59F4−$141,65745,772Direct
Jun 6, 2022Common StockSSaleDisposed−1,300$62.43F5−$81,15944,472Direct
Jun 6, 2022Common StockSSaleDisposed−115$63.40F6−$7,29144,357Direct
Jun 6, 2022Common StockSSaleDisposed−3,533$60.55F7−$213,923.1540,824Direct
Jun 6, 2022Common StockSSaleDisposed−3,650$61.59F8−$224,803.537,174Direct
Jun 6, 2022Common StockSSaleDisposed−1,891$62.48F9−$118,149.6835,283Direct
Jun 6, 2022Common StockSSaleDisposed−123$63.69F10−$7,833.8735,160Direct
Jun 8, 2022Common StockAGrant or awardAcquired+9,900$0.00$045,060Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 6, 2022Common StockMOption exerciseDisposed−6,250$0.00$00Direct
Jun 8, 2022Common StockAGrant or awardAcquired+24,800$0.00$024,800Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.23 to $61.22, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 3 through 10.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.23 to $62.17, inclusive.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.23 to $62.78, inclusive.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.29 to $64.14, inclusive.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.220 to $61.215, inclusive.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.22 to $62.18, inclusive.

Referenced by the price of 1 transaction in Table I.

F9

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.200 to $62.935, inclusive.

Referenced by the price of 1 transaction in Table I.

F10

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.60 to $64.06, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)